The company reported the preliminary results from an ongoing P-II (TELLOMAK) trial that evaluates lacutamab in patients with mycosis fungoides who express KIR3DL2 & were prior treated with two lines of systemic therapy
As of the data cutoff of Mar 2022, patients in the KIR3DL2-expressing MF patients (cohort 2) & non-expressing cohort (cohort 3), received a median of 4 & 4.5 prior systemic therapies & had a median follow-up of 12.2mos. & 13.8mos.; ORR (28.6% & 11.1%); m-PFS (12.0mos. & 8.5mos.); PFS @12mos. (53.6% & 39.6%)
The clinical responses & favorable safety profile were observed in the P-II (TELLOMAK) study along with the skin responses, grade ≥3 Treatment-related TEAEs (5.1%), AEs leading to patients discontinuation (2.6%)
Ref: Innate Pharma | Image: Innate Pharma
